US FDA approves Pfizer's blood cancer therapy

FILE PHOTO: A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo

(Reuters) -The U.S. Food and Drug Administration on Monday granted accelerated approval to Pfizer's therapy for treating patients with a type of blood cancer that is difficult to treat, the company said.

The health regulator's decision allows use of the therapy, branded as Elrexfio, in patients with multiple myeloma that is hard to treat or has come back after receiving four or more prior lines of certain classes of treatments.